Genital endometriosis and melatonin: a role in the pathogenesis and its possible use in the treatment of the disease

Abstract

Hypothesis/aims of study. Melatonin is found in almost all living organisms, the range of its effects being quite diverse. Effects of this hormone in the human body are realized via two ways, through specific receptors and non-receptor pathways. Melatonin may act through both membrane and nuclear receptors. In the present work, the expression of MTR1 and MTR2 melatonin receptors was studied in the eutopic endometrium and endometrioid heterotopies, and the level of melatonin metabolite, 6-sulfatoxymelatonin, in daily urine in patients with genital endometriosis (GE) was analyzed.

Study design, materials and methods. The experimental group included 67 patients of reproductive age with a verified diagnosis of GE, and the control group consisted of 18 individuals with an ovulatory menstrual cycle without gynecological pathology. The 6-sulfatoxymelatonin level in daily urine was determined by enzyme immunoassay. The study of MTR1 and MTR2 melatonin receptor expression in the endometrium and endometrioid heterotopies was performed in 24 patients with GE and in 10 women of reproductive age who were examined for infertility who did not have gynecological pathology based on diagnostic laparoscopy. To study the expression of melatonin receptors, the endometrium and endometrial heterotopy sampling was carried out from day 18 to day 22 of the menstrual cycle. Morphological assessment included histological and immunofluorescence studies using confocal laser scanning microscopy.

Results. In patients with GE, there was found a tendency to a decrease in 6-sulfatoxymelatonin excretion in daily urine compared to the control group. It was also found that the total relative expression area of melatonin receptors in the endometrium of women with GE was significantly lower compared to the endometrium of patients from the control group. Significant differences between the average brightness and optical density were not found. In addition, it was revealed that the relative expression areas of MTR1 and MTR2 melatonin receptors in the eutopic endometrium and in endometrioid heterotopies did not differ significantly. A negative correlation was stated between the relative expression area of melatonin receptors and GE prevalence. Particular attention is paid to the role of melatonin in the development of GE and to the possibilities of working out new treatment regimens with its use.

Conclusion. The data obtained confirm the undoubted role of melatonin in the pathogenesis of GE, however, the development of new treatment regimens with its use requires further study.

Keywords

melatonin / 6-sulfatoxymelatonin / MTR1 and MTR2 melatonin receptor expression / genital endometriosis

References

[1] Mahmood D. Pleiotropic effects of Melatonin. Drug Res (Stuttg). 2019;69(2):65-74. https://doi.org/10.1055/a-0656- 6643.

[2] Датиева В.К., Васенина Е.Е., Левин О.С. Перспективы применения мелатонина в клинической практике // Современная терапия в психиатрии и неврологии. — 2013. — № 1. — С. 47–51. [Datieva VK, Vasenina EE, Levin OS. Prospects of application of melatonin in clinical practice. Sovremennaya terapiya v psikhiatrii i nevrologii. 2013;(1):47-51. (In Russ.)]

[3] Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. — СПб.: Эко-Вектор, 2017. [Yarmolinskaya MI, Aylamazyan EK. Genital’nyy endometrioz. Razlichnye grani problemy. Saint Petersburg: Eko-Vektor; 2017. (In Russ.)]

[4] Light and Biological Rhythms in Man. Ed. by L. Wetterberg. Stockholm; 1994.

[5] Мелатонин: теория и практика / Под ред. С.И. Рапопорта, В.А. Голиченкова. — М.: Медпрактика-М, 2009. [Melatonin: teoriya i praktika. Ed. by S.I. Rapoport, V.A. Golichenkov. Moscow: Medpraktika-M; 2009. (In Russ.)]

[6] Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: Natureʼs most versatile biological signal? FEBS J. 2006;273(13):2813-2838. https://doi.org/10.1111/j.1742-4658.2006.05322.x.

[7] Beskonakli E, Palaoglu S, Aksaray S, et al. Effect of pinealectomy on immune parameters in rats with Staphylococcus aureus infection. Neurosurg Rev. 2001;24(1):26-30. https://doi.org/10.1007/pl00011962.

[8] Yan G, Yu L, Jiang S, Zhu J. Melatonin antagonizes oxidative stress-induced mitochondrial dysfunction in retinal pigmented epithelium cells via melatonin receptor 1 (MT1). J Toxicol Sci. 2018;43(11):659-669. https://doi.org/10.2131/jts.43.659.

[9] Schernhammer ES, Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004;90(5):941-943. https://doi.org/10.1038/sj.bjc.6601626.

[10] Bondy SC, Campbell A. Mechanisms underlying tumor suppressive properties of Melatonin. Int J Mol Sci. 2018;19(8). https://doi.org/10.3390/ijms19082205.

[11] Menendez-Menendez J, Martinez-Campa C. Melatonin: An anti-tumor agent in hormone-dependent cancers. Int J Endocrinol. 2018;2018:3271948. https://doi.org/10.1155/2018/3271948.

[12] Yang HL, Zhou WJ, Gu CJ, et al. Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. Am J Reprod Immunol. 2018;80(1):e12839. https://doi.org/10.1111/aji.12839.

[13] Yesildaglar N, Yildirim G, Yildirim OK, et al. The effects of melatonin on endometriotic lesions induced by implanting human endometriotic cells in the first SCID-mouse endometriosis-model developed in Turkey. Clin Exp Obstet Gynecol. 2016;43(1):25-30.

[14] Yilmaz B, Kilic S, Aksakal O, et al. Melatonin causes regression of endometriotic implants in rats by modulating angiogenesis, tissue levels of antioxidants and matrix metalloproteinases. Arch Gynecol Obstet. 2015;292(1):209-216. https://doi.org/10.1007/s00404-014-3599-4.

[15] Тхазаплижева С.Ш., Молотков А.С. Эффективность мелатонина в комбинированном лечении больных наружным генитальным эндометриозом // Журнал акушерства и женских болезней. — 2017. — Т. 66. — № S. — C. 151–152. [Tkhazaplizheva SS, Molotkov AS. Effektivnost’ melatonina v kombinirovannom lechenii bol’nykh naruzhnym genital’nym endometriozom. Journal of Obstetrics and Womenʼs Diseases. 2017;66(S):151-152. (In Russ.)]

[16] Zhao H, Pang SF, Poon AM. mt(1) Receptor-mediated antiproliferative effects of melatonin on the rat uterine antimesometrial stromal cells. Mol Reprod Dev. 2002;61(2):192-199. https://doi.org/10.1002/mrd.1147.

[17] Ness TJ. Not always lost in translation. Pain. 2013;154(6):775. https://doi.org/10.1016/j.pain.2013.03.022.

[18] Thompson C. Melatonin and the Mammalian Pineal Gland. Josephine Arendt. London: Chapman & Hall. 1995. 331 p. £49.50 (hb). Br J Psychiatry. 2018;167(3):419-419. https://doi.org/10.1192/s0007125000065296.

[19] Слесарева К.В. Клиническое значение факторов антиоксидантной защиты и клеточной регуляции у пациенток репродуктивного возраста с наружным генитальным эндометриозом: Автореф. дис. … канд. мед. наук. — Самара, 2015. [Slesareva KV. Klinicheskoe znachenie faktorov antioksidantnoy zashchity i kletochnoy regulyatsii u patsientok reproduktivnogo vozrasta s naruzhnym genital’nym endometriozom. [dissertation] Samara; 2015. (In Russ.)]

[20] Линде В.А., Ермолова Н.В., Слесарева К.В., и др. Клиническое значение мелатонина в развитии и прогрессировании наружного генитального эндометриоза у пациенток репродуктивного возраста // Главный врач Юга России. — 2016. — № 3. — С. 18–20. [Linde VA, Ermolova NV, Slesareva KV, et al. The clinical significance of melatonin in the development and progression of external genital endometriosis patients of reproductive age. Glavnyy vrach Yuga Rossii. 2016;(3):18-20. (In Russ.)]

[21] Плехова Е.И., Турчина С.И. Годовые и циркадные ритмы экскреции мелатонина у здоровых мальчиков-подростков / Проблемы детской эндокринологии: третий международный симпозиум компании «Ново Нордиск» (Дания); сентябрь 17–19, 1998; Крым. [Plekhova EI, Turchina SI. Godovye i tsirkadnye ritmy ekskretsii melatonina u zdorovykh mal’chikov-podrostkov. In: Proceedings of the 3rd International Symposium of the Novo Nordisk Company (Denmark) “Problemy detskoy endokrinologii’; 1988 Sep 17-19; Krym. (In Russ.)]

RIGHTS & PERMISSIONS

Yarmolinskaya M.I., Tkhazaplizheva S.S., Molotkov A.S., Tkachenko N.N., Borodina V.L., Andreyeva N.Y., Kleymyonova T.S., Lysenko V.V.